Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
about
GPR119, a novel G protein-coupled receptor target for the treatment of type 2 diabetes and obesityAtherogenic, fibrotic and glucose utilising actions of glucokinase activators on vascular endothelium and smooth muscleSitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.Exubera(®) (inhaled insulin): an evidence-based review of its effectiveness in the management of diabetesInvestigational agents that protect pancreatic islet beta-cells from failure.Selective PPAR modulators, dual and pan PPAR agonists: multimodal drugs for the treatment of type 2 diabetes and atherosclerosis.Practical review of oral antihyperglycemic agents for type 2 diabetes mellitus.Autonomic nervous system-dependent and -independent cardiovascular effects of exendin-4 infusion in conscious rats.The role of vildagliptin in the management of type 2 diabetes mellitus.Type 2 diabetes: an expanded view of pathophysiology and therapy.Peptide and protein drugs: the study of their metabolism and catabolism by mass spectrometry.GPR119 agonists as potential new oral agents for the treatment of type 2 diabetes and obesity.A site-specific PEGylated analog of exendin-4 with improved pharmacokinetics and pharmacodynamics in vivo.Improving the anti-diabetic activity of GLP-1 by fusion with globular adiponectin.Possible involvement of GLP-1(9-36) in the regional haemodynamic effects of GLP-1(7-36) in conscious rats.In vitro metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223.Dipeptidylpeptidase--IV, a key enzyme for the degradation of incretins and neuropeptides: activity and expression in the liver of lean and obese rats.Altered dipeptidyl peptidase-4 activity during the progression of hyperinsulinemic obesity and islet atrophy in spontaneously late-stage type 2 diabetic rats.
P2860
Q24653673-0FD32E1D-23A4-4715-9716-75AC67675A94Q33593675-A93A1278-E29F-476C-BB41-E129CDCB3C4DQ34569365-6E3F7735-27A8-4CD5-BFE7-2E1E1A8C9966Q35876380-C3F3D29A-5CBE-4E35-B1FF-98344F92E1A2Q36268360-C8877E0B-23B6-4B10-B49B-DBEA9547FDD6Q36580568-B443BA00-C999-48F0-9585-6FF281824AC8Q36652827-87C45296-7E0B-488F-875C-4BA733B10915Q36735857-4ABB577D-829C-4D7F-8ACF-D2FE9D37C5E2Q36800624-AD3ACFC4-C195-4D96-B5E2-50C8326A7DDBQ37750278-CEAAF084-CA25-4723-AC0C-CCDF24FA602EQ37893563-F31732EC-AE87-44B3-8E97-CC41D675C5A4Q38089183-3F47CFD5-5A6D-4EB9-B30D-5A64D2353A75Q39537998-004CA55F-4B96-4128-81E3-238BB5FE7E40Q39569931-91D038A8-D3A0-487C-A5DA-517DAD8C04FBQ41809232-BFF5794C-5A02-4F4E-98F2-2EDD68254A50Q42484308-FC64AA16-A2F2-44E5-BA8A-8A69559F229BQ43218274-DCFD51C3-EEA1-4D25-B6E7-E185AC9F534AQ48167168-14D9521A-581A-4AD4-9785-43BCD750E37A
P2860
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
@ast
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
@en
type
label
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
@ast
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
@en
prefLabel
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
@ast
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
@en
P1433
P1476
Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes.
@en
P2093
Loretta L Nielsen
P304
P356
10.1016/S1359-6446(05)03460-4
P577
2005-05-01T00:00:00Z